论文部分内容阅读
目的:观察阿托伐他汀联合介入封堵术对先天性心脏病动脉导管未闭合并中重度肺动脉高压(PAH)患者的影响。方法 :选择介入封堵治疗的PAD伴中重度PAH患者共62例,随机分为阿托伐他汀组及对照组,各31例。分别在介入封堵术前及术后6个月检测6分钟步行距离(6MWT)、平均肺动脉压(m PAP)的变化、血浆内皮素-1(ET-1)及PGI2(稳定代谢产物6-Keto-PGFIα浓度)变化。结果:治疗6个月后,2组患者6MWT及6-Keto-PGFIα浓度较术前增加(P<0.05),阿托伐他汀组较对照组增加更明显(P<0.05),2组患者m PAP及ET-1较术前均减少(P<0.05),阿托伐他汀组较对照组减少更明显(P<0.05)。结论:成人房间隔缺损(ASD)合并中重度PAH在介入封堵术基础上联合阿托伐他汀治疗可进一步降低肺动脉压力及血浆ET-1水平、增加PGI2及6MWT,改善心功能。
Objective: To observe the effect of atorvastatin combined with occlusion on patients with patent ductus arteriosus and moderate and severe pulmonary hypertension (PAH) in patients with congenital heart disease. Methods: A total of 62 patients with moderate to severe PAH who underwent occlusion therapy were randomly divided into atorvastatin group and control group, with 31 cases in each group. The 6-minute walking distance (6MWT), mean pulmonary artery pressure (mPa), plasma endothelin-1 (ET-1) and PGI2 (stable metabolite 6- Keto-PGFIα concentration). Results: After 6 months treatment, the concentrations of 6MWT and 6-Keto-PGFIα in two groups increased (P <0.05), compared with those in control group (P <0.05) PAP and ET-1 decreased compared with preoperative (P <0.05), atorvastatin decreased more significantly than control group (P <0.05). Conclusions: Adult ASD combined with moderate and severe PAH combined with atorvastatin can further decrease pulmonary artery pressure and plasma ET-1 level, increase PGI2 and 6MWT, and improve cardiac function.